|
|
||||||||
1-Crystallin Enhancer Influences Mouse
A-Crystallin Promoter Activity in Transgenic Mice
1From the Department of Ophthalmology and the 4School of Medicine, University of Missouri, Columbia, Missouri; and the 3Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, Texas.
| Abstract |
|---|
|
|
|---|
A-crystallin (or
A) promoters have been effective at driving transgene expression in lens fiber cells, but not in lens epithelium. Because the chick
1-crystallin gene is expressed in lens epithelial cells, an enhancer was borrowed from this gene and linked to the
A promoter. This heterogenic enhancer/promoter construct was tested in transgenic mice to see whether it was active in both lens epithelium and fiber cells while retaining lens specificity.
METHODS. The third intron of the chick
1-crystallin gene, which contains a lens enhancer element, was added to the 5' end of the mouse
A promoter. We refer to this chimeric regulatory element as the
en
A promoter. To test its activity, we inserted coding sequences for five different genes. Transgenic mice were generated by pronuclear microinjection. Transgene expression patterns were analyzed by either X-gal staining, in situ hybridization or immunohistochemical staining.
RESULTS. When
en
A-lacZ transgenic embryos were stained with X-gal at embryonic day (E)11.5, ß-galactosidase activity was detected only in the eye. Histologic sections of the stained embryos revealed that lacZ was expressed exclusively in the lens, in both epithelial and fiber cells. Transgenic mice were also generated using either the original
A- or the new
en
A promoter linked to an insulin cDNA. In situ hybridizations confirmed that the short
A promoter targeted prenatal insulin expression specifically to the lens fiber cells, whereas the
en
A promoter was active in both lens epithelial and fiber cells. Developmental studies of the
en
A-insulin mice showed that the
en
A promoter became active at the lens pit stage and remained active in all lens cells, even at postnatal ages. The
en
A promoter also successfully directed expression of SV40 T-antigen (TAg), human E2F2, and dominant negative Sprouty2 (dn-Spry2) genes to lens epithelial and fiber cells. The lens specificity of the
en
A promoter was maintained in minigenes with different types of introns and polyadenylation signals.
CONCLUSIONS. A new lens-specific regulatory element was generatedthe
en
A promoter, which can drive high levels of transgene expression in both lens epithelium and fiber cells throughout development. This modified promoter can be used for future transgenic studies of signal transduction and cell cycle regulation in lens epithelial cells.
A-crystallin promoter has been used to obtain lens-specific gene expression in transgenic mice, thereby allowing in vivo modifications of lens differentiation and development.4 5 6 7 For example, central lens epithelial cells can be induced to differentiate into lens fiber cells in transgenic mice by expression of secreted fibroblast growth factors (FGFs) under the control of the
A-crystallin promoter.8 This promoter has been used in transgenic mice to express growth factors,6 7 9 10 cell cycle regulators,4 5 11 and transcription factors12 that modify lens and eye development.
Although the mouse
A-crystallin promoter is active in the lens, its activity in lens epithelial cells is much lower than its activity in lens fiber cells, based on in situ hybridization assays.13 It would be useful to have a promoter with high activity in all lens cells. Such a promoter would be especially valuable for experiments designed to activate or inhibit intracellular signal-transduction pathways before the onset of fiber cell differentiation. The
B-crystallin promoter and the Pax6 surface ectodermal P0 promoter can direct transgene expression to lens epithelial and fiber cells.14 15 However, transgene expression is not limited to the lens.14 15 Because the
A-crystallin promoter is lens specific, we tested whether addition of an enhancer might expand its domain of activity.
-Crystallin is a major lens protein in birds and reptiles.16 The
1-crystallin gene is expressed abundantly in the embryonic chick lens and is detected in the lens epithelium from the onset of lens differentiation.17 This lens-specific expression is regulated by an enhancer element that is located in the third intron of the gene.18 Although
1-crystallin gene is not present in mammals, the cloned chick gene is expressed in a lens-specific manner in transgenic mice,19 suggesting that the transregulatory proteins responsible for lens-specific expression of
1-crystalllin are conserved across species. The chick
1-crystallin enhancer, when linked to the Hsp68 promoter, can direct transgene (lacZ) expression in both lens epithelial and fiber cells in the transgenic mouse embryo.20 It is not clear whether the
1-crystallin enhancer is also capable of directing transgene expression in the postnatal mouse lens.
Based on these previous studies, we tested the consequences of adding the
1-crystallin enhancer to the 5' end of the
A-crystallin promoter. This new chimeric promoter was termed
en
A. We constructed five different minigenes and tested them for expression in transgenic mice. Herein, we provide evidence that the
en
A promoter can drive transgene expression in both lens epithelial and fiber cells throughout development while remaining lens specific.
| Materials and Methods |
|---|
|
|
|---|
en) containing the chick
1-crystallin lens enhancer element was generously provided by Hisato Kondoh (Osaka University, Osaka, Japan).18 This enhancer is approximately 1 kb in length and spans the entire third intron of the
1-crystallin gene. A KpnI-BglII fragment (1 kb) containing the enhancer was linked to a KpnI-BglIIdigested mouse
A crystallin promoter vector plasmid.21 22 The resultant plasmid was modified by deleting the EcoRI site in the
A-crystallin promoter.
We constructed two promoter vectors for transgene expression (see Fig. 1 ). For vector 1, an adenovirus intron (minx) from Sue Berget (Baylor College of Medicine, Houston, TX)23 and a 230-bp polyA signal from the mouse
B crystallin gene were used. The
B polyA sequences were amplified by polymerase chain reaction (PCR), using primers, 5'-TCCCCCGGGTAGATCCCCTTTCCTCATTG-3' (sense) and 5'-GCTCAGACCCCTGAATCATAGTTTG-3' (antisense) and then digested with XmaI and XbaI for cloning. For vector 2, the
en
A promoter was placed upstream from a rabbit ß-globin intron and human growth hormone (hGH) polyA signal.24 25
|
A-insulin minigene (see Fig. 3A ), or blunt ended and inserted into the SmaI site of vector 2 to make the
en
A-insulin minigene (see Fig. 3B ). (3) The SV40 early region (approximately 2.7 kb) was released from the
A-cry-TAg plasmid26 by BamHI/EcoRI digestion and inserted into a BamHI/EcoRI digest of vector 1 to make the
en
A-TAg minigene (see Fig. 6 ). (4) To construct
en
A-E2F2, the human cDNA was isolated from CPV2-E2F211 by digestion with EcoRI (blunt ended) and then ClaI. The fragment was inserted into a SmaI/ClaI digest of vector 1 (see Fig. 7 ). (5) The dn-Spry2 cDNA clone was provided by Eisuke Nishida (Kyoto University, Kyoto, Japan).27 The cDNA fragment was cut out by BglII digestion, blunted with T4 DNA polymerase, and inserted into the SmaI site of vector 2 (see Fig. 8 ).
|
|
|
|
|
Genomic DNAs from mouse tails or embryonic tissues were isolated and subjected to PCR screening according to procedures described previously.13 For transgenic mice that were made with Pax6-lacZ (Fig. 2B) , CPV2-insulin (see Fig. 3A ), and
en
A-TAg (see Fig. 6 ), primers specific for SV40 sequences were used (SV40A, 5'-GTGAAGGAACCTTACTCTGTGGTG-3'; SV40B, 5'-GTCCTTGGGGTCTTCTACCTTTCTC-3').13 For transgenic mice that were made with vector 1, including
en
A-lacZ (see Fig. 2A ) and
en
A-E2F2 (see Fig. 7 ), we used primers homologous to the mouse
A-crystallin promoter and the minx intron. They are 5'-GCATTCCAGCTGCTGACGGT-3' (Pr4, sense) and 5'-AGAGGATCCCCACTGGAAAGAC-3' (minx, antisense). To screen the mice made with minigenes in vector 2, including
en
A-insulin (see Figs. 3B 4 5 ) and
en
A-dnSpry2 (see Fig. 8 ), we used Pr4 as the sense primer along with an antisense primer (ß3, 5'-AAGGCATGAACATGGTTAGCAGAGG-3') homologous to the rabbit ß-globin intron sequences.
|
|
In Situ Hybridization
We used in situ hybridizations to detect expression of the other transgenes.30 For transgenes made in vector 2 (see Figs. 3B 4 5 8 ), we subcloned the human growth hormone (hGH) polyA sequences into the EcoRI site of a plasmid (Bluescript SK; Stratagene, La Jolla, CA). The orientation of the hGH insert was determined by DNA sequencing. Sense and antisense riboprobes were generated from linearized DNA templates by in vitro transcription using T3 or T7 RNA polymerase (Promega, Madison, WI). For transgenic mice carrying CPV2-insulin (see Fig. 3A ) or
en
A-TAg (see Fig. 6B 6C 6D 6E ), a riboprobe specific to the SV40 sequences was made as previously described.13 For the
en
A-E2F2 mice (see Fig. 7 ), the human E2F2 cDNA was subcloned into the plasmid pBluescript and used to generate riboprobes.11 Tissues for analysis were fixed, embedded, sectioned, and then hybridized to 35S-labeled riboprobes. After the slides were washed and dried, they were dipped in emulsion (NTB-2; Eastman Kodak, Rochester, NY) and exposed at 4°C for 2 to 7 days before development (D-19 developer; Eastman Kodak). The slides were counterstained with Harris hematoxylin (PolyScientific). In situ hybridization signals were captured as bright- or dark-field images.
Immunohistochemistry
Mouse tissues were fixed, processed, and sectioned for immunohistochemistry as previously described.31 After pretreatment with 5% normal goat serum, tissue sections were incubated at 4°C overnight with a monoclonal antibody against SV40 T-antigen (TAg; BD Biosciences, Palo Alto, CA). Sections were rinsed with PBS and incubated with fluorescein-labeled anti-mouse IgG (Sigma-Aldrich, St. Louis, MO) at room temperature for 1 hour, to reveal the TAg localization. After they were rinsed with PBS, slides were mounted in PBS with 50% glycerol for examination and photography under blue-light illumination.
| Results |
|---|
|
|
|---|
A-crystallin gene is activated at embryonic day (E)10.5 in the lens vesicle and remains expressed postnatally.32 A 400-bp mouse
A-crystallin (
A) promoter (366/+43) has been used successfully to drive high levels of transgene expression in mouse lens.4 13 33 One feature of the short promoter is that its activity is much higher in lens fiber cells than in lens epithelial cells in transgenic mice (see Fig. 3A , for example). For studies of cell cycle regulation and signal transduction in lens epithelial cells, it would be preferable to use a promoter that gives high levels of transgene expression in the lens epithelial cells. It has been reported that the proximal promoter (P0) of the Pax6 gene can drive transgene expression in both lens epithelial and fiber cells (Fig. 2B) .15 34 However, this promoter is active in other ocular tissues including corneal, conjunctiva, and glandular epithelium (Fig. 2B) .
-Crystallin is the most abundantly expressed crystallin in chick lens.16 The third intron of the
1-crystallin gene contains an enhancer element that determines the lens-specific expression of the gene.18 In this study, we modified the mouse short
A promoter by adding the
1-crystallin enhancer (
en) to the 5' end of the promoter. We named the chimeric regulatory element the
en
A promoter. To test its activity in transgenic mice, we first constructed a lacZ reporter minigene (Fig. 2A) . The bacterial lacZ gene was flanked by a small intron from adenovirus (called minx) at its 5' end and a polyA signal from the mouse
B-crystallin gene (
BpA) at its 3' end. Two transgenic founder embryos were isolated at E11.5 and stained for ß-galactosidase activity. Both embryos gave the staining pattern shown in Figure 2A . The eye was the only tissue that stained blue in the whole embryo (Fig. 2A , left). When the stained embryos were sectioned, X-gal staining was detected only in the lens (Fig. 2A , middle), and was present in both lens epithelial and fiber cells (Fig. 2A , right).
To compare the specificity of the
A and
en
A promoters, they were linked to the same reporter gene, human insulin cDNA (Fig. 3) . We generated two transgenic lines with the
A-insulin minigene (CPV2-insulin). In both lines, in situ hybridization detected transgene expression only in the lens fiber cells (Fig. 3A) . Using the
en
A-insulin construct, six transgenic lines were established (LR12-14, -16, -20, and -22). In situ hybridizations performed on five of these lines showed transgene expression in both lens epithelial and fiber cells (Fig. 3B) . Different transgenic lines had different levels of transgene expression (Fig. 3B) . In general, the expression level was higher in the lens epithelial cells than in the fiber cells (except for line LR16).
We also investigated the time course of
en
A promoter activity using three of the insulin transgenic lines (Figs. 4 5) . In the strong-expressing line LR22, we did not detect transgene expression in the lens placode but expression was detected readily in the cells of the lens pit (Figs. 4A 4B) . In other lines, transgene expression was detected in the late lens pit or early lens vesicle stage (Figs. 4C 4D 4E 4F ; see also Figs. 7A 7B 7C 7D ', and Fig. 8A ). High levels of transgene expression were found in newborn (postnatal day [P]0), P7, and P30 lenses (Fig. 5) . Thus, the
en
A promoter remains active postnatally in the mouse, despite the fact that
1-crystallin gene expression is turned off in chicks after hatching.16
We made additional minigenes using either vector 1 (Figs. 6 7) or vector 2 (Fig. 8) . For example, the
en
A promoter was linked to the SV40 early region, which encodes large TAg (Fig. 6) . This construct was used to establish four transgenic lines, OVE1664, -1765, -1766, and -1767. Mice from all four lines exhibited lens tumors. Tumors were not found in other parts of the body. For OVE1664, in situ hybridizations showed that the transgene is expressed in all lens cells at E15.5 (Figs. 6C 6E) . Protein expression in these cells was confirmed by fluorescent immunolabeling using an anti-TAg antibody (Fig. 6G) .
For the E2F2 minigene (
en
A-minx-E2F2-
BpA; Fig. 7 ), two E15.5 transgenic founder embryos were isolated and tested for transgene expression by in situ hybridization using a probe homologous to the human E2F2 cDNA sequences. One founder embryo showed transgene expression in both lens epithelial and fiber cells, and the other had expression only in the fiber cells (data not shown). We also generated three stable transgenic lines (OVE1586, -1587, and -1588). Mice from line 1588 did not show any lens defects and transgene expression was not detected by reverse transcription (RT)-PCR analysis (data not shown). Cataracts developed in mice from lines OVE1586 and -1587. In situ hybridization showed that the transgene was expressed in both lens epithelial and fiber cells in line OVE1587 (Fig. 7) . At E10.5, a low level of transgene mRNA was detected in the lens pit. Transgene expression levels increased during prenatal development (Figs. 7D 7E 7F '). In line OVE1586, E2F2 mRNA was detected only in lens fiber cells, by in situ hybridization (data not shown). The same pattern of expression occurred in CPV2-E2F2 transgenic mice.11
Recently, we generated nine transgenic founder mice with the
en
A-dnSpry2 minigene (Fig. 8) . The minigene was constructed using vector 2, as for the
en
A-insulin minigene (Fig. 3B) . Seven of the nine founder mice had cataracts with different degrees of severity. The founder mice were bred to the wild-type FVB/N mice to establish stable transgenic lines. In the severely affected lines (e.g., line LR40), a low level of transgene expression was first detected in the lens pit (Fig. 8A , E10.5) and then the expression level increased as lens development proceeded. At E12.5, high levels of transgene expression were found in both lens epithelial and fiber cells (Fig. 8A , E12.5), even though the expression level was still lower than that in most of the insulin families (Fig. 3B) . Transgene expression was also compared in the different dn-Spry2 lines (Fig. 8B) . In the low-expressing line (e.g., line LR44), transgene mRNA was not found in the lens pit but was detectable in the lens vesicle (data not shown). Among the three lines tested at E13.5, transgene expression was found in both lens epithelial and fiber cells. The levels are higher in lines LR37 and -40 than in line -44 (Fig. 8B) .
In summary, we have now tested five minigenes in two different
en
A promoter vectors. Transgene expression was detected in both lens epithelial and fiber cells in 14 of the 16 integration sites that were assayed. Expression of the transgene begins at the lens pit stage of lens development or shortly thereafter. To date, expression has been detected only in the lens. No expression was seen in other regions of the eye or in other tissues of the embryos.
| Discussion |
|---|
|
|
|---|
A-crystallin promoter (366/+43) in the mouse has been used previously to target transgene expression to the lens.11 35 36 37 This promoter is significantly more active in lens fiber cells than in lens epithelial cells (see Fig. 3A , for example). In this study, we have added the chick
1-crystallin enhancer to the short mouse
A-crystallin promoter. This new promoter,
en
A, was linked to four cDNAs (lacZ, insulin, E2F2 and dn-Spry2) and a viral gene SV40 T-antigen. These constructs were tested in transgenic mice. Each transgene was found to be expressed in a lens-specific fashion, often in both lens epithelial and fiber cells. In the
en
A-insulin mice, transgene expression was not found in the lens placode but was detected before closure of the lens pit during early lens development. Expression was still strong more than 4 weeks after birth. In the
en
A-dnSpry2 mice, a low level of transgene expression in the lens pit was detectable only in the high-expressing lines. The lens specificity of the
en
A promoter was retained with two different promoter vectors, 1 and 2 (Fig. 1) . We conclude that this novel chimeric promoter can be used to target transgene expression to all cells of the lens, beginning at the lens pit stage or shortly thereafter. A few transgenic families (2/16) had low or no expression in lens epithelial cells (e.g., the
en
A-E2F2 families), suggesting that some integration sites can inhibit the activity of the enhancer.
1-Crystallin is abundantly expressed in the embryonic chick lens but is not present in the mammalian genome.16 38 39 40 Nevertheless, the
1-crystallin regulatory elements function in a lens-specific manner in transgenic mice.19 41 This suggests that the trans-acting regulatory factors for
1-crystallin expression are present in the mouse lens. Kondohs group has shown that Sox, Pax6, and Maf transcription factors act together to regulate
1-crystallin enhancer activity.20 42 43 Sox2 (or Sox1/Sox3) pairs with Pax6 to form an activation complex. Maf proteins augment the enhancer activity in fiber cells. Because the Sox, Pax6, and Maf genes are all expressed in the mouse lens during development,44 45 46 47 48 it is likely that these transcription factors are recruited by the
1-enhancer into the chimeric regulatory element, thereby promoting transgene expression in lens epithelial cells. Our results suggest that the short
A-crystallin promoter can be influenced by, or can respond to, transcriptional regulators that do not bind to the promoter directly. The short promoter is not active, or weakly active, in lens epithelial cells. However, it is capable of being activated in these cells.
In our study, the
en
A promoter was active in the lens epithelium and fibers in 1-month-old postnatal lenses (Fig. 5) . This finding is intriguing because
1-crystallin expression is turned off in the chick lens after hatching. Negative regulatory sites presumably exist in the chick
1-crystallin gene to downregulate its expression after hatching. Such elements may not be contained within the 1-kb enhancer we used or, alternatively, may not bind to mouse proteins that can downregulate promoter activity.
It is worthwhile to mention that in four of the five
en
A-insulin transgenic lines we assayed (LR12, -13, -14, and -22; Fig. 3B ), the transgene expression level was higher in the lens epithelial cells than in the fiber cells. It is known that insulin and insulin-like growth factors (IGFs) can stimulate chick, but not mouse, lens epithelial cells to differentiate into fiber cells.49 50 51 In the
en
A-insulin transgenic mice, the lens epithelial cells did not undergo premature differentiation. However, we cannot rule out the possibility that insulin produced from the transgenic lens may enhance the
en
A chimeric promoter activity through a positive feedback mechanism.
Pax6 plays a key role in eye and lens morphogenesis and development. There are three conserved transcription start sites (P0, P1, and
) in the mouse Pax6 locus.15 Independent cis-regulatory elements have been identified, which control the tissue-specific patterns of expression of Pax6.29 34 For example, Pax6 expression in the surface ectoderm is, at least in part, regulated by a highly conserved enhancer element located approximately 4 kb upstream of the P0 promoter in the mouse Pax6 gene.29 34 This enhancer was shown to be sufficient to target expression of a lacZ reporter gene to the lens and corneal epithelium (Fig. 2B) .34 Using a strategy and logic similar to the
-enhancer experiments, we linked the Pax6 lens enhancer to the mouse
A-crystallin promoter. Transgenic mice were generated with the Pax6 enhancer-
A promoter linked to lacZ, FGF15, or p57/Kip2 (data not shown). The transgenic mice did not show consistent expression in lens epithelium and a significant fraction (almost 50%) showed no expression in the lens (data not shown). In contrast to the
1-crystallin enhancer, the Pax6 enhancer did not cooperate effectively with the short
A-crystallin promoter.
Although the endogenous
A-crystallin gene is expressed in lens epithelial cells, the short promoter has little or no activity in these cells. We presume that there are regulatory sequences used by the endogenous gene that are not included in the short promoter. These endogenous sequences have not been identified, but they may be located some distance from the short promoter. We also tested a longer promoter (1.3 kb) but did not see transgene expression in the epithelial cells (data not shown). The endogenous regulation of
A-crystallin expression may therefore involve communication and cooperation between the short promoter and more distant enhancer elements. The chick
1-crystallin enhancer is apparently able to cooperate in an analogous way to induce the short promoter to be active in lens epithelial cells. The strategy of using an enhancer/promoter chimera to obtain stronger tissue-specific gene expression has been reported previously.52 53 For example, a skeletal muscle gene (creatine kinase) enhancer was fused to the smooth muscle specific SM22
promoter to achieve stronger transgene expression in smooth muscle cells.53 In our case, it is intriguing that the enhancer/promoter fusion changes the cell type specificity of the promoter but the promoter still remains tissue specific.
In summary, we generated a new lens-specific promoter,
en
A, that can direct transgene expression to both prenatal and postnatal lens epithelial and fiber cells. Unlike the mouse
B-crystallin and Pax6 P0 promoters, the
en
A promoter is lens specific. Transgene expression was not detected in the cornea. This promoter should be particularly useful for transgenic studies of signal transduction and cell physiology in lens epithelial cells in vivo. It can also be used to express Cre and/or Flp recombinases to perform lens-specific gene deletion experiments in mice.
| Acknowledgements |
|---|
en
A-lacZ minigene, respectively; Venkatesh Govindarajan, Lingkun Kong, and Barbara Harris for X-gal staining; Li Xu for constructing the
en
A-insulin minigene; Shan-yu Ho for genotyping the transgenic mice; the Transgenic Animal Core Facility at the University of Missouri-Columbia for generating the LR transgenic families; and Ales Cvekl at Albert Einstein College of Medicine for valuable and insightful discussions. | Footnotes |
|---|
Supported by National Eye Institute Grants EY13146 (LWR) and EY10448 (PAO), core Grant EY14795, a departmental unrestricted grant from Research to Prevent Blindness Inc. (LWR), and a fellowship award from Knights Templar Eye Foundation (QC).
Submitted for publication November 20, 2003; revised April 12 and July 11, 2004; accepted July 20, 2004.
Disclosure: L.W. Reneker, None; Q. Chen, None; A. Bloch, None; L. Xie, None; G. Schuster, None; P.A. Overbeek, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Lixing W. Reneker, EC214 Mason Eye Institute, One Hospital Dr., Columbia, MO 65212; renekerl{at}health.missouri.edu.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
X. Fan, L. W. Reneker, M. E. Obrenovich, C. Strauch, R. Cheng, S. M. Jarvis, B. J. Ortwerth, and V. M. Monnier Vitamin C mediates chemical aging of lens crystallins by the Maillard reaction in a humanized mouse model PNAS, November 7, 2006; 103(45): 16912 - 16917. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||